CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Favipiravir and HydroxychloroquineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2668 VivaDiag™ COVID-19 lgM/IgG Rapid Test Wiki 1.00

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19

This study is a randomized, open-label, parallel groups multi-centered trial were participants are assigned to either an intervention arm ( a combination of Favipiravir and Hydroxychloroquin) or standard of care.

NCT04392973 COVID19 Combination Product: Favipiravir and Hydroxychloroquine

Primary Outcomes

Description: The primary endpoint is the time to clinical improvement, defined as the time from the randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first.

Measure: Clinical Improvement

Time: 28 days

Secondary Outcomes

Description: PCR test negative conversion days from positive to negative.

Measure: Viral shedding

Time: 28 days

No related HPO nodes (Using clinical trials)